Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel

Sayaka Sobue, Naoki Mizutani, Yuka Aoyama, Yoshiyuki Kawamoto, Motoshi Suzuki, Yoshinori Nozawa, Masatoshi Ichihara, Takashi Murate

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Paclitaxel (PTX) is a microtubule-targeting drug widely used for the treatment of a variety of cancers. However, drug resistance can emerge after a series of treatments, and this can seriously affect the patient's prognosis. Here, we analyzed the mechanism of PTX resistance using a human prostate cancer cell line, PC3, and its PTX-resistant subline, PC3-PR. Compared with PC3, PC3-PR exhibited some unique phenotypes that might be associated with PTX resistance, including decreased expression of acetylated α-tubulin and the cell cycle regulator p21, and increased expression of βIII tubulin, histone deacetylase 6 (HDAC6), and the anti-apoptotic protein Bcl2. The drug exporters MDR1 and MRP1 were not involved in PTX resistance. Although cabazitaxel (CTX), a novel taxoid, has been reported to overcome PTX resistance, its mechanism of action is unknown. We found that treatment of PC3-PR cells with CTX induced expression of acetylated α-tubulin and p21, but not the related regulators p27, p15, and p16 or the Bcl2 family proteins. The pan-HDAC inhibitors trichostatin A and suberanilohydroxamic acid and the HDAC6-specific inhibitor tubacin inhibited PC3-PR proliferation and increased expression of p21 and acetylated α-tubulin in a manner similar to CTX. Our data shed light on the cellular response to PTX and CTX.

Original languageEnglish
Pages (from-to)808-813
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume479
Issue number4
DOIs
Publication statusPublished - 28-10-2016
Externally publishedYes

Fingerprint

Paclitaxel
Prostatic Neoplasms
Cells
Cell Line
Tubulin
Histone Deacetylases
trichostatin A
Cyclin-Dependent Kinase Inhibitor p21
Taxoids
Apoptosis Regulatory Proteins
Histone Deacetylase Inhibitors
Drug Delivery Systems
cabazitaxel
Drug Resistance
Microtubules
Pharmaceutical Preparations
Therapeutics
Phenotype
Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Sobue, Sayaka ; Mizutani, Naoki ; Aoyama, Yuka ; Kawamoto, Yoshiyuki ; Suzuki, Motoshi ; Nozawa, Yoshinori ; Ichihara, Masatoshi ; Murate, Takashi. / Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel. In: Biochemical and Biophysical Research Communications. 2016 ; Vol. 479, No. 4. pp. 808-813.
@article{9a0ac2cef3df4daa83d7bb377259e1dd,
title = "Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel",
abstract = "Paclitaxel (PTX) is a microtubule-targeting drug widely used for the treatment of a variety of cancers. However, drug resistance can emerge after a series of treatments, and this can seriously affect the patient's prognosis. Here, we analyzed the mechanism of PTX resistance using a human prostate cancer cell line, PC3, and its PTX-resistant subline, PC3-PR. Compared with PC3, PC3-PR exhibited some unique phenotypes that might be associated with PTX resistance, including decreased expression of acetylated α-tubulin and the cell cycle regulator p21, and increased expression of βIII tubulin, histone deacetylase 6 (HDAC6), and the anti-apoptotic protein Bcl2. The drug exporters MDR1 and MRP1 were not involved in PTX resistance. Although cabazitaxel (CTX), a novel taxoid, has been reported to overcome PTX resistance, its mechanism of action is unknown. We found that treatment of PC3-PR cells with CTX induced expression of acetylated α-tubulin and p21, but not the related regulators p27, p15, and p16 or the Bcl2 family proteins. The pan-HDAC inhibitors trichostatin A and suberanilohydroxamic acid and the HDAC6-specific inhibitor tubacin inhibited PC3-PR proliferation and increased expression of p21 and acetylated α-tubulin in a manner similar to CTX. Our data shed light on the cellular response to PTX and CTX.",
author = "Sayaka Sobue and Naoki Mizutani and Yuka Aoyama and Yoshiyuki Kawamoto and Motoshi Suzuki and Yoshinori Nozawa and Masatoshi Ichihara and Takashi Murate",
year = "2016",
month = "10",
day = "28",
doi = "10.1016/j.bbrc.2016.09.128",
language = "English",
volume = "479",
pages = "808--813",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "4",

}

Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel. / Sobue, Sayaka; Mizutani, Naoki; Aoyama, Yuka; Kawamoto, Yoshiyuki; Suzuki, Motoshi; Nozawa, Yoshinori; Ichihara, Masatoshi; Murate, Takashi.

In: Biochemical and Biophysical Research Communications, Vol. 479, No. 4, 28.10.2016, p. 808-813.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel

AU - Sobue, Sayaka

AU - Mizutani, Naoki

AU - Aoyama, Yuka

AU - Kawamoto, Yoshiyuki

AU - Suzuki, Motoshi

AU - Nozawa, Yoshinori

AU - Ichihara, Masatoshi

AU - Murate, Takashi

PY - 2016/10/28

Y1 - 2016/10/28

N2 - Paclitaxel (PTX) is a microtubule-targeting drug widely used for the treatment of a variety of cancers. However, drug resistance can emerge after a series of treatments, and this can seriously affect the patient's prognosis. Here, we analyzed the mechanism of PTX resistance using a human prostate cancer cell line, PC3, and its PTX-resistant subline, PC3-PR. Compared with PC3, PC3-PR exhibited some unique phenotypes that might be associated with PTX resistance, including decreased expression of acetylated α-tubulin and the cell cycle regulator p21, and increased expression of βIII tubulin, histone deacetylase 6 (HDAC6), and the anti-apoptotic protein Bcl2. The drug exporters MDR1 and MRP1 were not involved in PTX resistance. Although cabazitaxel (CTX), a novel taxoid, has been reported to overcome PTX resistance, its mechanism of action is unknown. We found that treatment of PC3-PR cells with CTX induced expression of acetylated α-tubulin and p21, but not the related regulators p27, p15, and p16 or the Bcl2 family proteins. The pan-HDAC inhibitors trichostatin A and suberanilohydroxamic acid and the HDAC6-specific inhibitor tubacin inhibited PC3-PR proliferation and increased expression of p21 and acetylated α-tubulin in a manner similar to CTX. Our data shed light on the cellular response to PTX and CTX.

AB - Paclitaxel (PTX) is a microtubule-targeting drug widely used for the treatment of a variety of cancers. However, drug resistance can emerge after a series of treatments, and this can seriously affect the patient's prognosis. Here, we analyzed the mechanism of PTX resistance using a human prostate cancer cell line, PC3, and its PTX-resistant subline, PC3-PR. Compared with PC3, PC3-PR exhibited some unique phenotypes that might be associated with PTX resistance, including decreased expression of acetylated α-tubulin and the cell cycle regulator p21, and increased expression of βIII tubulin, histone deacetylase 6 (HDAC6), and the anti-apoptotic protein Bcl2. The drug exporters MDR1 and MRP1 were not involved in PTX resistance. Although cabazitaxel (CTX), a novel taxoid, has been reported to overcome PTX resistance, its mechanism of action is unknown. We found that treatment of PC3-PR cells with CTX induced expression of acetylated α-tubulin and p21, but not the related regulators p27, p15, and p16 or the Bcl2 family proteins. The pan-HDAC inhibitors trichostatin A and suberanilohydroxamic acid and the HDAC6-specific inhibitor tubacin inhibited PC3-PR proliferation and increased expression of p21 and acetylated α-tubulin in a manner similar to CTX. Our data shed light on the cellular response to PTX and CTX.

UR - http://www.scopus.com/inward/record.url?scp=84991696104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991696104&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2016.09.128

DO - 10.1016/j.bbrc.2016.09.128

M3 - Article

C2 - 27687545

AN - SCOPUS:84991696104

VL - 479

SP - 808

EP - 813

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 4

ER -